Symbiotic Health Inc

The microbiome is an ecosystem of symbiotic bacteria that protect us from dangerous intestinal infections. Antibiotics can injure the microbiome, allowing Clostridium difficile (Cdiff) infection to take hold. Cdiff, which causes severe, debilitating diarrhea, is the most frequent hospital-acquired infection in the US and “an immediate public health threat that requires urgent and immediate action” (CDC). Cdiff is involved in over 330,000 US hospitalizations per year. Incidence and deaths have increased 400% since 2000 (CDC). Standard therapy fails for over 20% of patients, often leading to chronic diarrhea lasting months or years, with poor outcomes, impaired function and billions of excess medical expenses per year. Cdiff is one of several antibiotic-resistant intestinal infections which are a global public health threat.

Symbiotic Health Inc is a New York-based biotechnology company focused on the development of novel therapies for C. difficile. Our pipeline includes a capsule microbiome therapeutic designed to cure Cdiff by restoring a community of protective bacteria. The potential of microbiome restoration as a treatment for gastrointestinal infection has been recognized for decades, but has never been commercialized due to fundamental technological limitations. Our proprietary technology addresses key challenges for the development and production of microbiome-based therapies.

For more information, please contact ghonig@symbioticbio.com.

Please click here to sign our mailing list